Complete Filing Data
Anebulo Pharmaceuticals, Inc. reported Stockholders Equity of $10.60 million for FY2023.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Anebulo Pharmaceuticals, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income Loss | -$8.5M | -$8.2M | -$11.7M | -$6.8M | -$30.3M |
| Research And Development Expense | $4.3M | $3.5M | $5.6M | $3.0M | $2.3M |
| Operating Expenses | $9.2M | $8.3M | $11.8M | $6.8M | $3.6M |
| General And Administrative Expense | $4.9M | $4.8M | $6.2M | $3.9M | $1.3M |
| Operating Income Loss | -$9.2M | -$8.3M | -$11.8M | -$6.8M | -$3.6M |
| Other Nonoperating Income Expense | -$1.2K | $9.3K | -$41.1K | -$1.8K | -$1.3K |
| Nonoperating Income Expense | $738.7K | $107.1K | $51.3K | $5.6K | -$26.6M |
| Interest Expense Nonoperating | $382.0K | $151.2K | |||
| Net Income Loss Available To Common Stockholders Basic | -$6.8M | -$38.5M | |||
| Interest Expense | $11.8K | ||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$3.6M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Loss | -$2.0M | -$2.2M | -$1.7M | -$2.5M | -$2.2M | -$1.7M | -$2.7M | -$2.5M | -$2.8M | -$3.8M | -$2.6M | -$1.9M | -$1.1M | -$1.6M | -$555.8K | -$328.6K | -$256.4K | -$174.6K |
| Research And Development Expense | $1.2M | $810.0K | $638.3K | $1.2M | $1.3M | $748.3K | $1.1M | $1.3M | $1.1M | $1.9M | $1.2M | $915.4K | $212.9K | $715.1K | $273.0K | $170.0K | $20.3K | $150.0K |
| Operating Expenses | $2.6M | $2.3M | $1.9M | $2.6M | $2.4M | $1.7M | $2.8M | $2.5M | $2.9M | $3.8M | $2.6M | $1.9M | $1.1M | $1.6M | $552.1K | $324.6K | $252.3K | $173.4K |
| General And Administrative Expense | $1.5M | $1.5M | $1.3M | $1.4M | $1.1M | $915.9K | $1.7M | $1.3M | $1.8M | $1.9M | $1.4M | $964.3K | $858.2K | $839.8K | $279.1K | $154.6K | $232.1K | $23.4K |
| Operating Income Loss | -$2.6M | -$2.3M | -$1.9M | -$2.6M | -$2.4M | -$1.7M | -$2.8M | -$2.5M | -$2.9M | -$3.8M | -$2.6M | -$1.9M | -$1.1M | -$1.6M | -$552.1K | -$324.6K | ||
| Other Nonoperating Income Expense | -$34.00 | -$96.00 | -$528.00 | $47.00 | -$283.00 | $2.3K | -$594.00 | $7.7K | -$13.1K | -$22.6K | -$212.00 | $3.2K | -$1.9K | |||||
| Nonoperating Income Expense | $620.5K | $101.9K | $216.2K | $125.1K | $211.4K | $10.7K | $43.1K | $62.9K | $66.1K | -$13.8K | -$212.00 | $3.2K | $1.5K | -$3.7K | -$4.0K | -$1.3K | ||
| Interest Expense Nonoperating | $17.4K | $17.4K | $245.2K | $59.7K | $59.7K | $59.7K | $31.8K | |||||||||||
| Net Income Loss Available To Common Stockholders Basic | -$1.9M | -$8.8M | -$174.6K | |||||||||||||||
| Interest Expense | $59.7K | $31.8K | $3.7K | $1.3K | ||||||||||||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$1.6M | -$555.8K | -$252.3K | -$173.4K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Stockholders Equity | $10.6M | $15.1M | $21.4M | -$171.1K | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $11.2M | $14.5M | $20.0M | $3.0M | ||
| Retained Earnings Accumulated Deficit | -$65.4M | -$57.2M | -$45.5M | -$38.6M | -$183.1K | |
| Liabilities And Stockholders Equity | $4.1M | $11.7M | $15.6M | $21.7M | $3.0M | |
| Liabilities | $260.6K | $1.1M | $512.5K | $241.6K | $223.9K | |
| Common Stock Value | $25.9K | $25.6K | $23.3K | $23.3K | $12.0K | |
| Assets | $4.1M | $11.7M | $15.6M | $21.7M | $3.0M | |
| Accrued Liabilities Current | $104.2K | $534.3K | $131.7K | $131.6K | $22.6K | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $8.5M | -$8.2M | -$3.3M | -$5.4M | $17.0M | |
| Accounts Payable Current | $156.4K | $534.5K | $380.8K | $110.0K | ||
| Cash And Cash Equivalents At Carrying Value | $3.1M | $11.2M | ||||
| Assets Current | $3.5M | $11.7M | ||||
| Cash | $3.1M | $11.2M | ||||
| Other Assets Noncurrent | $565.1K | |||||
| Prepaid Expense And Other Assets Current | ||||||
| Preferred Stock Dividends Income Statement Impact | $8.2M | |||||
| Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction | $654.0K | |||||
| Grant Receivable | ||||||
| Offering Costs Included In Accounts Payable | ||||||
| Non Cash Deemed Dividend | $8.2M | |||||
| Temporary Equity Carrying Amount Attributable To Parent | $3.0M | |||||
| Repayments Of Related Party Debt | $201.3K | |||||
| Promissory Notes Accrued Interest | ||||||
| Cashless Exercise Of Warrants Into Convertible Preferred Stock | $37.1M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $7.9M | $9.7M | $11.7M | $13.5M | $15.0M | $1.9M | $3.8M | $5.0M | $6.5M | $8.3M | $12.9M | $15.5M | $19.1M | $17.2M | $18.9M | $19.9M | -$9.4M | -$719.0K | -$411.1K | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $9.0M | $10.4M | $11.6M | $13.3M | $15.0M | $1.4M | $3.1M | $5.1M | $6.6M | $8.5M | $14.2M | $16.4M | $19.2M | $16.5M | $18.0M | $19.2M | $3.3M | $2.5M | $2.9M | ||
| Retained Earnings Accumulated Deficit | -$78.0M | -$76.0M | -$73.9M | -$71.7M | -$70.1M | -$67.6M | -$64.1M | -$62.4M | -$59.7M | -$54.7M | -$51.9M | -$48.1M | -$43.1M | -$41.3M | -$40.2M | -$9.5M | |||||
| Liabilities And Stockholders Equity | $9.4M | $10.7M | $12.1M | $14.0M | $15.8M | $2.5M | $6.0M | $7.5M | $9.0M | $14.4M | $16.9M | $19.8M | $17.2M | $19.0M | $20.5M | $4.3M | |||||
| Liabilities | $1.5M | $963.8K | $487.7K | $546.0K | $878.8K | $569.2K | $1.0M | $1.0M | $716.6K | $1.5M | $1.4M | $698.2K | $85.8K | $49.9K | $607.7K | $10.8M | |||||
| Common Stock Value | $41.1K | $41.1K | $41.1K | $41.1K | $41.1K | $25.9K | $25.9K | $25.9K | $25.6K | $25.6K | $25.6K | $25.6K | $23.3K | $23.3K | $23.3K | $13.0K | |||||
| Assets | $9.4M | $10.7M | $12.1M | $14.0M | $15.8M | $2.5M | $6.0M | $7.5M | $9.0M | $14.4M | $16.9M | $19.8M | $17.2M | $19.0M | $20.5M | $4.3M | |||||
| Accrued Liabilities Current | $930.8K | $356.3K | $263.5K | $118.5K | $559.3K | $317.1K | $625.4K | $694.9K | $150.6K | $920.2K | $1.0M | $174.7K | $2.5K | $7.0K | $113.9K | $211.1K | |||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$1.3M | -$1.7M | -$2.7M | $4.7M | -$777.9K | -$135.0K | $3.0M | ||||||||||||||
| Accounts Payable Current | $554.9K | $607.5K | $224.2K | $427.6K | $319.5K | $252.1K | $384.9K | $318.7K | $565.9K | $570.9K | $346.6K | $523.5K | $83.3K | $42.9K | $493.8K | $82.0K | |||||
| Cash And Cash Equivalents At Carrying Value | $9.0M | $10.4M | $11.6M | $13.3M | $15.0M | $1.4M | $5.1M | $6.6M | $8.5M | $3.3M | $3.0M | ||||||||||
| Assets Current | $9.3M | $10.5M | $12.0M | $13.8M | $15.4M | $2.0M | $5.4M | $6.8M | $3.9M | $3.0M | |||||||||||
| Cash | $9.0M | $10.4M | $11.6M | $13.3M | $15.0M | $1.4M | $5.1M | $6.6M | $8.5M | $3.3M | $3.0M | ||||||||||
| Other Assets Noncurrent | $148.2K | $165.7K | $183.1K | $200.5K | $445.7K | $505.4K | $624.8K | $684.5K | |||||||||||||
| Prepaid Expense And Other Assets Current | $700.7K | $954.9K | $1.3M | $1.7M | $591.7K | ||||||||||||||||
| Preferred Stock Dividends Income Statement Impact | $8.2M | ||||||||||||||||||||
| Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction | |||||||||||||||||||||
| Grant Receivable | $56.8K | $9.8K | $73.2K | ||||||||||||||||||
| Offering Costs Included In Accounts Payable | $248.9K | ||||||||||||||||||||
| Non Cash Deemed Dividend | |||||||||||||||||||||
| Temporary Equity Carrying Amount Attributable To Parent | $3.0M | ||||||||||||||||||||
| Repayments Of Related Party Debt | |||||||||||||||||||||
| Promissory Notes Accrued Interest | $4.0K | $1.3K | |||||||||||||||||||
| Cashless Exercise Of Warrants Into Convertible Preferred Stock |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Share Based Compensation | $1.4M | $758.9K | $884.7K | $480.7K | $199.9K |
| Net Cash Provided By Used In Operating Activities | -$6.3M | -$8.1M | -$9.7M | -$5.4M | -$4.9M |
| Increase Decrease In Accrued Liabilities | $159.4K | -$430.1K | $402.6K | $118.00 | $109.0K |
| Increase Decrease In Accounts Payable | $67.7K | -$378.1K | $153.7K | $270.8K | $110.0K |
| Increase Decrease In Prepaid Expense | -$152.4K | -$9.0K | -$608.2K | -$636.9K | $1.7M |
| Net Cash Provided By Used In Financing Activities | $14.9M | -$62.4K | $6.4M | $21.8M | |
| Proceeds From Issuance Of Common Stock | $15.0M | $6.6M | $20.6M | ||
| Payments Of Stock Issuance Costs | $116.7K | $62.4K | $317.1K | ||
| Proceeds From Stock Options Exercised | $52.4K | ||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $1.7M | ||||
| Payments For Repurchase Of Initial Public Offering | $821.6K | ||||
| Payments Of Financing Costs | $116.7K | $62.4K | |||
| Increase Decrease In Grant Receivable | -$73.2K | ||||
| Increase Decrease In Accounts Receivable Related Parties | -$3.5K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Based Compensation | $198.5K | $237.6K | $300.0K | $564.3K | $286.9K | $200.0K | $200.0K | $210.8K | $200.0K | $200.0K | $211.9K | $125.3K | $94.3K | $34.2K | $47.4K | $20.7K | $16.4K | |
| Net Cash Provided By Used In Operating Activities | -$1.3M | -$1.7M | -$2.7M | -$2.0M | -$777.9K | -$135.0K | -$150.8K | |||||||||||
| Increase Decrease In Accrued Liabilities | $92.8K | $212.9K | -$383.6K | $43.0K | -$17.7K | $50.6K | $22.6K | |||||||||||
| Increase Decrease In Accounts Payable | $383.4K | $95.7K | $31.4K | -$106.3K | $383.8K | $166.4K | ||||||||||||
| Increase Decrease In Prepaid Expense | -$90.7K | -$100.9K | $104.6K | -$429.3K | -$375.2K | |||||||||||||
| Net Cash Provided By Used In Financing Activities | $6.7M | $3.2M | ||||||||||||||||
| Proceeds From Issuance Of Common Stock | $6.6M | |||||||||||||||||
| Payments Of Stock Issuance Costs | $37.6K | |||||||||||||||||
| Proceeds From Stock Options Exercised | $52.4K | |||||||||||||||||
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$375.2K | $42.6K | ||||||||||||||||
| Payments For Repurchase Of Initial Public Offering | $248.9K | |||||||||||||||||
| Payments Of Financing Costs | ||||||||||||||||||
| Increase Decrease In Grant Receivable | $63.4K | -$245.4K | ||||||||||||||||
| Increase Decrease In Accounts Receivable Related Parties |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.25 | -$0.32 | -$0.47 | $0.29 | -$2.83 | |
| Common Stock Shares Authorized | 50.0M | 40.0M | 40.0M | 40.0M | 22.8M | |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Weighted Average Number Of Shares Outstanding Basic | 33.8M | 25.8M | 25.1M | 23.3M | 13.6M | |
| Earnings Per Share Basic | $-0.25 | $-0.32 | $-0.47 | $0.29 | $-2.83 | |
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Common Stock Shares Outstanding | 25.9M | 25.6M | 23.3M | 23.3M | 12.0M | |
| Common Stock Shares Issued | 25.9M | 25.6M | 23.3M | 23.3M | 12.0M | |
| Preferred Stock Shares Authorized | 2.0M | 0.00 | 0.00 | 0.00 | ||
| Weighted Average Number Of Diluted Shares Outstanding | 33.8M | 25.8M | 25.1M | 23.3M | ||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | ||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 13.6M | |||||
| Weighted Average Number Of Shares Outstanding Basic And Diluted | ||||||
| Net Loss Per Share Basic And Diluted | ||||||
| Temporary Equity Shares Outstanding | ||||||
| Temporary Equity Shares Issued |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.05 | -$0.05 | -$0.04 | -$0.09 | -$0.08 | -$0.06 | -$0.11 | -$0.10 | -$0.11 | -$0.15 | -$0.11 | -$0.05 | -$0.07 | -$0.68 | -$0.03 | -$0.02 | -$0.01 | |||
| Common Stock Shares Authorized | 75.0M | 75.0M | 75.0M | 50.0M | 50.0M | 50.0M | 50.0M | 50.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 40.0M | 50.0M | 22.8M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||
| Weighted Average Number Of Shares Outstanding Basic | 41.1M | 41.1M | 41.1M | 27.4M | 25.9M | 25.9M | 25.8M | 25.6M | 25.6M | 25.6M | 23.4M | 23.3M | 23.3M | 23.3M | ||||||
| Earnings Per Share Basic | $-0.05 | $-0.05 | $-0.04 | $-0.09 | $-0.08 | $-0.06 | $-0.11 | $-0.10 | $-0.11 | $-0.15 | $-0.11 | $-0.08 | $-0.05 | $-0.07 | ||||||
| Preferred Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |||||||
| Common Stock Shares Outstanding | 41.1M | 41.1M | 41.1M | 41.1M | 41.1M | 25.9M | 25.9M | 25.9M | 25.6M | 25.6M | 25.6M | 25.6M | 23.3M | 23.3M | 23.3M | 13.0M | ||||
| Common Stock Shares Issued | 41.1M | 41.1M | 41.1M | 41.1M | 41.1M | 25.9M | 25.9M | 25.9M | 25.6M | 25.6M | 25.6M | 25.6M | 23.3M | 23.3M | 23.3M | 13.0M | ||||
| Preferred Stock Shares Authorized | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | 2.0M | |||||||
| Weighted Average Number Of Diluted Shares Outstanding | 41.1M | 41.1M | 41.1M | 27.4M | 25.9M | 25.9M | 25.8M | 25.6M | 25.6M | 25.6M | 23.4M | |||||||||
| Preferred Stock Shares Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||
| Preferred Stock Shares Issued | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||
| Weighted Average Number Of Share Outstanding Basic And Diluted | 23.3M | 23.3M | 13.0M | 13.0M | 12.0M | 12.0M | ||||||||||||||
| Weighted Average Number Of Shares Outstanding Basic And Diluted | 23.3M | 13.0M | ||||||||||||||||||
| Net Loss Per Share Basic And Diluted | $-0.08 | $-0.68 | ||||||||||||||||||
| Temporary Equity Shares Outstanding | 2.0M | 2.0M | ||||||||||||||||||
| Temporary Equity Shares Issued | 2.0M | 2.0M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $1.4M | $758.9K | $884.7K | $480.7K | $199.9K |
| Additional Paid In Capital | $69.2M | $67.8M | $60.5M | $60.0M | |
| Prepaid Expense Current | $413.8K | $422.7K | $1.0M | $1.7M | |
| Interest Income Other | $257.9K | $249.0K | $92.4K | $7.3K | $1.0K |
| Stock Issued During Period Value New Issues | $14.9M | $654.0K | $6.3M | ||
| Amortization Of Financing Costs | $382.0K | $151.2K | |||
| Grant Income Other | $864.0K | ||||
| Stock Issued During Period Value Stock Options Exercised | $52.4K | ||||
| Investment Income Net | |||||
| Dividends | $8.2M | ||||
| Stock Issued During Period Shares Stock Options Exercised | 24.0K | ||||
| Other Expenses | |||||
| Interest Paid Net | $13.1K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q1 2021 | Q4 2020 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $198.5K | $237.6K | $255.3K | $564.3K | $286.9K | $151.6K | $219.3K | $210.8K | $223.6K | $225.6K | $211.9K | $125.3K | $94.3K | $34.2K | $47.4K | $20.7K | $16.4K | ||
| Additional Paid In Capital | $85.9M | $85.7M | $85.5M | $85.2M | $85.0M | $69.5M | $69.0M | $68.9M | $68.0M | $67.6M | $67.4M | $67.2M | $60.3M | $60.2M | $60.1M | $83.5K | |||
| Prepaid Expense Current | $175.4K | $170.8K | $261.4K | $528.0K | $366.3K | $312.9K | $223.7K | $171.7K | $527.3K | $267.8K | $532.9K | $601.7K | |||||||
| Interest Income Other | $85.4K | $109.6K | $102.3K | $7.1K | $26.0K | $68.1K | $75.5K | $55.2K | |||||||||||
| Stock Issued During Period Value New Issues | $15.0M | $654.0K | $6.4M | $3.5K | |||||||||||||||
| Amortization Of Financing Costs | $17.4K | $59.7K | |||||||||||||||||
| Grant Income Other | $552.6K | $9.8K | $359.6K | $177.7K | $245.4K | ||||||||||||||
| Stock Issued During Period Value Stock Options Exercised | $52.4K | ||||||||||||||||||
| Investment Income Net | $68.1K | $75.5K | $79.2K | $8.8K | |||||||||||||||
| Dividends | $8.2M | ||||||||||||||||||
| Stock Issued During Period Shares Stock Options Exercised | 24.0K | ||||||||||||||||||
| Other Expenses | $1.9K | $4.0K | |||||||||||||||||
| Interest Paid Net |
Most recent annual filing with the SEC: September 29, 2025
Data sourced from SEC EDGAR public filings as of August 7, 2026.